Primary amoebic meningoencephalitis: amoebicidal effects of clinically approved drugs against Naegleria fowleri

References

1. Baig A. M., Iqbal J., Khan N. A. 2013; In vitro efficacies of clinically available drugs against growth and viability of an Acanthamoeba castellanii keratitis isolate belonging to the T4 genotype. Antimicrob Agents Chemother 57:3561–3567 [View Article][PubMed]
   [Google Scholar]
2. Brunton L. L., Chabner B. A., Knollman B. C. 2011 Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 12th edn. New York: McGraw-Hill;
   [Google Scholar]
3. Marciano-Cabral F., Cabral G. A. 2007; The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunol Med Microbiol 51:243–259 [View Article][PubMed]
   [Google Scholar]
4. Siddiqui R., Khan N. A. 2011; Rigorous ablution is a potential risk factor to fatal brain infection in developing countries. J Infect 63:487–488 [View Article][PubMed]
   [Google Scholar]
5. Visvesvara G. S., Moura H., Schuster F. L. 2007; Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 50:1–26 [View Article][PubMed]
   [Google Scholar]
6. Yousuf F. A., Siddiqui R., Subhani F., Khan N. A. 2013; Status of free-living amoebae (Acanthamoeba spp., Naegleria fowleri, Balamuthia mandrillaris) in drinking water supplies in Karachi, Pakistan. J Water Health 11:371–375 [View Article][PubMed]
   [Google Scholar]